# Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

> **NCT02157051** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Washington** · enrollment: 42 (actual)

## Conditions studied

- HER2 Negative Breast Carcinoma
- Recurrent Breast Carcinoma
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer
- Stage III Breast Cancer

## Interventions

- **BIOLOGICAL:** CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02157051
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-06
- **Primary completion:** 2022-11-25
- **Final completion:** 2026-09-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02157051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02157051, "Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02157051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*